Our Pipeline

Pan-Amyloid Removal & Reversal Of The Underlying Pathology Of Systemic Amyloidosis

Making New Solutions Possible for Patients

AT ATTRALUS, WE SEE A CLEAR FUTURE WHERE MORE IS POSSIBLE FOR PATIENTS WITH SYSTEMIC AMYLOIDOSIS.

Using our proprietary pan-amyloid removal (PAR) technology, we are advancing a pipeline of novel therapeutics that remove toxic, disease-causing amyloid throughout the body with high specificity, and the potential to reverse disease pathology. We are pioneering first-in-class novel pan-amyloid therapies that bind to all types of amyloid, so that our therapies can be used for patients with all types of systemic amyloidosis and at all stages of disease.

Why It Matters

There is a critical unmet need for disease modifying therapies that can remove amyloid across all stages and types of systemic amyloidosis. The existing approved drugs for amyloidosis do not address the toxic amyloid deposits that are present and accumulate in organs and are the cause of disease burden, progressive organ failure and increased mortality in patients.

Our Pioneering Pan-Amyloid Pipeline

Attralus Novel Pan-Amyloid Targeting Pipeline updated Sep 2022

Our Pan-Amyloid Removal (PAR) Therapeutics

With the aim to treat all types of patients with systemic amyloidosis and open the door to reversing disease, at Attralus we are advancing our pipeline of product candidates for pan-amyloid removal. We have designed our novel biologics to achieve pan-amyloid removal with superior amyloid binding and immune-mediated phagocytosis.

AT-02: Pan-Amyloid Reactive Peptide-mAb Fusion Designed for Strong Binding and Phagocytosis (PAR-Peptide Technology)

AT-02

PAR-Peptide + IgG1 Antibody

AT-02 is a fusion of our PAR-peptide with an IgG1 antibody. The proprietary peptide binds to all types of amyloid and delivers the antibody to the site of disease to stimulate the immune system to remove amyloid.

AT-03 SAP-Fc Fusion Protien

AT-03

PAR-SAP + SAP ScFc

AT-03 is a fusion of our PAR-SAP with an IgG1 Fc. The PAR-SAP component mediates binding to all types of amyloid and the ScFc stimulates the immune system to remove amyloid.

AT-04 peptide-Fc fusion

AT-04

PAR-Peptide + Fc

AT-04 is a fusion of our PAR-peptide with the Fc component of an IgG1 antibody. The PAR-Peptide mediates binding to all types of amyloid and the Fc stimulates the immune system to remove amyloid.

AT-06 peptide CAR-M fusion

AT-06

PAR-Peptide + CAR-M

AT-06 is a fusion of our PAR-peptide with human chimeric antigen receptor-macrophages (CAR-M). The use of the CAR in human THP-1 cells enhances phagocytosis of human amyloid extracts.

Our Amyloid-Specific Imaging Agents

In support of our therapeutic strategy, we are also developing the world’s first amyloid-specific imaging agent which will improve the clinical journey for patients and dramatically expand the population of those who are diagnosed.

 

AT-01 Iodine (I-124) evuzamitideDiagnostic Imaging agent for systemic amyloidosis

AT-01
Iodine (I-124) evuzamitide

PAR-Peptide + I-124

AT-01 utilizes our pan-amyloid technology combined with iodine-124 to create an amyloid-specific imaging agent for PET/CT imaging to diagnose and quantify systemic amyloidosis. The peptide radiotracer has been shown in clinical studies to detect many types of amyloid, including AL and ATTR, in major organs such as the heart, kidney, liver and spleen.

AT-06 Diagnostic Imaging agent for systemic amyloidosis

AT-05

PAR-Peptide + 99m Tc

AT-05 utilizes our pan-amyloid technology combined with technetium-99m to create an amyloid-specific imaging agent for SPECT/CT imaging.